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Quantitative Studies on the In Vitro
Metabolic Activation of Dimethylnitrosamine
by Rat Liver Postmitochondrial Supernatant
by David J. Doolittle*t and Jay 1. Goodman**
The metabolic activation ofdimethylnitrosamine (DMN) to mutagenic and/or cytotoxic intermediates in
vitro has been characterized and the relationship between DMN demethylase and ethoxyresorufin-O-
deethylase (EROD) or ethylmorphine-N-demethylase (EMND) has been evaluated. A mammalian assay
system which uses the postmitochondrial supernatant (S-15 fraction) prepared from a rat liver homogenate
as an enzyme source and V79 Chinese hamster cells as targets for chemically induced damage was used.
The enzyme pattern ofthe S-15 fraction was altered by pretreatment ofexperimental animals in vivo and/or
by the use of enzyme inhibitors in vitro.
The results ofthese studies indicate that the concentration of S-15 fraction in the reaction mixture can
markedly influence the degree of DMN-induced cytotoxicity when it is metabolized in vitro and that the
degree ofDMN-induced cytotoxicity and mutagenicity are linearly related. The degree ofcytotoxicity and
mutagenicity induced in V79 cells by DMN does not correlate with EROD activity (a measure of
3-methylcholanthrene-inducible mixed-function oxidases) nor with EMND activity (a measure of
phenobarbital-inducible mixed function oxidases) in the S-15 fraction.
Introduction
The metabolic activation system incorporated into
short-term mutagenicity assays usually consists of a
hepatic postmitochondrial supernatant (PMS) along
with selected cofactors. The mixed-function oxidase
system in ahepatic PMS is known to consists ofmultiple
cytochrome P-450 isozymes with different, but overlap-
ping substrate specification. The ability of a given PMS
enzymatically to deethylate ethoxyresorufin or to
demethylate ethylmorphine is often used to characterize
the profile of cytochrome P-450s present.
Although each of these reactions is likely to be
catalyzed by more than one isozyme of cytochrome
P-450, the rate ofeach reaction is clearly a marker for a
different pattern of mixed function oxidase activity.
Ethoxyresorufin-O-deethylase (EROD) activity is con-
sidered to be a measure of 3-methylcholanthrene(MC)-
inducible mixed-function oxidase activity, while ethyl-
morphine-N-demethylase (EMND) activity is consid-
ered to be a measure ofphenobarbital-inducible mixed-
function oxidase activity. The relationship between
these widely used mixed-function oxidase "marker
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activities" and the ability to metabolically activate
carcinogens and mutagens is poorly understood.
Dimethylnitrosamine (DMN) is a hepatocarcinogenic
nitrosamine (1,2) that requires metabolic activation in
order to function as a mutagen (3-6), although at high
concentrations DMN is cytotoxic in the absence of
metabolic activation due to its protein denaturing
ability, which may result in cell membrane destruction
(7).
The metabolic activation of DMN is catalyzed by (an)
enzyme(s) termed DMN demethylase (8). The de-
methylase activity in an in vitro metabolic activation
system correlates, in some cases, with DMN-induced
mutagenicity (9-11), whereas in other instances DMN
demethylase activity does not correlate with DMN-
induced mutagenesis (12). Isolated microsomes from
mouse livers exhibit only about half the DMN
demethylase activity present in the crude homogenate
(13-15). The enhancing effect of the soluble fraction
may be due to the presence of additional cofactors for
the microsomal enzymes because the hepatic soluble
fraction is unable to metabolize DMN in the absence of
microsomes(14-16). RecentevidencesuggeststhatDMN
demethylase may be composed of several mixed-
function oxidases (17-19). The objective of the experi-
ments reported here was to determine whether the
cytochrome P-450 isozymes which comprise DMN
demethylase activity correlate with EMND activity or
with EROD activity.DOOLITTLE AND GOODMAN
Materials and Methods
Materials
Calf serum, antibiotics and culture medium were
purchased from Gibco (Grand Island, NY). Ouabain,
NADPH, NADP, NADH, glucose-6-phosphate, glucose-
6-phosphate dehydrogenase, 3-methylcholanthrene,
trypsin, dimethylnitrosamine, metyrapone, a-napht-
hoflavone and bovine serum albumin were obtained from
Sigma Chemical Co. (St. Louis, MO). ,B-Naphthoflavone
was from Aldrich Chemical Co. (Milwaukee, WI)
phenobarbital from Mallinckrodt (St. Louis, MO), and
Giemsa stain (improved R66 solution) from Biomedical
Specialties (Santa Monica, CA). Aroclor 1254 brand of
polychlorinated biphenyls (PCB) (Monsanto Chemical
Co., St. Louis, MO) was a gift from J. B. Hook,
Michigan State University.
Cell Line and Culture Conditions
The cells used in these experiments are V79 Chinese
hamster cells that grow in monolayer (obtained as a gift
from J. E. Trosko and C. C. Chang, Michigan State
University). This cell line was derived from the lung ofa
normal, male Chinese hamster (20). The cells are
routinely cultured at 37°C in humid air containing 5%
C02, in modified Eagle's minimal essential medium
(Gibco formula 78-5470) supplemented with 20% (v/v)
calf serum, penicillin (100 units/mL), streptomycin (100
,ig/mL), fungizone (0.25 ,ug/mL), sodium pyruvate
(110 ,xg/mL), glucose (lmg/mL), sodium chloride (0.83
mg/mL) and sodium bicarbonate (1 mg/mL).
Preparation of Hepatic Postmitochondrial
Supernatant (S-15 fraction)
Male Sprague-Dawley rats (Spartan Research Farms,
Haslett, MI) weighing 180 to 240 g were maintained on
a 12 hr light cycle (7 P.M.-7A.M.), allowed free access to
food (Wayne Lab-Blox, Allied Mills, Chicago, IL) and
water, and they were acclimated to our animal quarters
for at least 3 days prior to use.
Groups ofanimals were pretreated with IP injections
of MC (80 mg/kg body weight in peanut oil, 24 hr prior
to sacrifice), BNF (80 mg/kg body weight in peanut oil,
24 hr prior to sacrifice), Aroclor 1254 brand ofPCB (500
mg/kgbody weight in peanut oil, 96 hrprior to sacrifice)
or phenobarbital (80 mg/kg body weight in isotonic
NaCl solution, 96, 72, 48 and 24 hr prior to sacrifice).
Controls received vehicle only.
The hepatic postmitochondrial supernatant is pre-
pared (5) as aseptically as possible, at 0 to 4°C, just
prior to use. Animals are killed by a sharp blow to the
back of the head followed by cervical dislocation. The
liver is removed, washed with 0.9% saline, and homoge-
nized with a Potter-Elvehjem type homogenizer in 3
volumes of sucrose-HEPES buffer (0.25 M sucrose
containing 2mM MgCl2 and 20 mM N-2-hydroxyethyl-
piperazine-N'-2-ethanesulfonic acid, pH 7.4). The
homgenate then undergoes two successive centrifuga-
tions (Sorvall RC 2-B refrigerated centrifuge); 9000 g
for 10 min. followed by 15,000 g for 20 min. The
postmitochondrial supernatant obtained is referred to
as the S-15 fraction.
Cytotoxicity and Mutagenicity Assays
The assays were performed in the following manner.
Stock cultures ofV79 cells in the midlogarithmic phase
of growth were trypsinized (0.01% crystalline trypsin
dissolved in phosphate-buffered saline, pH 7.8, 37°C; 10
min and the cell number determined with a hemo-
cytometer. Thecellsaredilutedtothedesiredconcentra-
tion and seeded into 10 mL of warm (25°C) growth
medium in 100-mmtissue culture dishes. The numberof
cells seeded per dish is 200 to 2000 for cytotoxicity
assessmentand 1 x 105to 5 x 105forthedetermination
ofmutation frequency. The actual number is dependent
upon the anticipated toxicity of a particular treatment.
The same stock population of V79 cells is used for
parallel determinations of cytotoxicity and mutation
frequency.
The cells are allowed 6 hr to attach to the culture
dishes. The growth medium is then removed and the
treatment medium is added. This consists of the fol-
lowing components, added in order: (1) 5.9 mL
phosphate-buffered saline (PBS) (8 g NaCl, 0.2 g KCl,
1.15 g Na2HPO4, 0.2 g KH2PO4/L glass-distilled water,
pH 7.3); (2) 2.0 mL ofthe cofactor mixture, composed of
the following (final concentration in the reaction
mixture) dissolved in 66 mMTris-HCl, pH 7.5: NADPH,
0.1 mM; NADP, 0.3 mM; NADH, 0.4 mM; MgCl2, 3.0
mM; glucose-6-phosphate, 4.2 mM; and glucose-
6-phosphate dehydrogenase, 1 unit/mL; (3) 2.0 mL of
the S-15 fraction, diluted with sucrose-HEPES buffer
to give the desired final protein concentration in the
treatment medium; (4) 0.1 mL of DMN diluted with
glass-distilled water. When enzyme inhibitors are
employed, the volume ofPBS is reduced to 5.8 mL and
0.1 mL of the inhibitor dissolved in the appropriate
solvent (metyrapone: 66 mM Tris-HCI, pH 7.5;
a-naphthoflavone:dimethyl sulfoxide) is added. Controls
lack S-15 and cofactors orthe test compound or allthree
of these components.
The pH ofthe treatment medium is 7.5 when the test
compound is added. After the tissue culture dishes have
been placed in the incubator (5% CO2 in air) the pH
drops to 7.0 and remains at this value forthe duration of
treatment.
Following a 2-hr incubation, the treatment medium is
removed, the tissue culture dishes are washed once with
10 mL of phosphate-buffered saline and 10 mL of
growth medium are added. The PBS and growth
medium are warmed to room temperature prior to
addition to avoid cold-stressing the cells. The cells to be
used in the assessment of cytotoxicity are allowed to
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grow for 7 to 9 days, at which time the colonies that
form are stained (25 mL Giemsa stain, 30 mL absolute
methanol, 945 mL glass-distilled water) and counted.
Cytotoxicity is expressed as cloning efficiency relative
to control. The cells to be used for the determination of
mutation frequency are allowed an expression period
equal to the time it takes for them to divide four times
(16-cell stage, 48-80 hr after removal ofthe treatment
medium, depending upon treatment toxicity). This is
monitored with an inverted microscope. At this time,
growth medium is removed and selective medium is
added. The selectivemediumconsists ofgrowthmedium
containing 1 mM ouabain. The selective medium is
changed 3 and 8 days after addition to remove dead cells
and replenish nutrients. After 12 to 15 days ofgrowth in
the selective medium, the colonies which have formed
are stained and counted. Mutation frequency is
expressed on a per-survivor basis.
Enzyme Assays
Ethoxyresorufin-O-deethylase (EROD). EROD
activity was assayed by a modification (21) of a pre-
viously described procedure (22). The amount of
resorufin produced is quantified by comparison to a
standard curve. The resorufin obtained from the sup-
plier was recrystallized by dissolving in absolute
ethanol, filtering (0.22 ,um Millipore filter) and evapo-
rating to dryness. The purified resorufin was redis-
solved in absolute ethanol for construction of the
standard curve.
Ethylmorphine-N-demethylase (EMND). EMND
activity was assayed as previously described (23). The
amount of formaldehyde produced is determined by
comparison to a standard curve constructed by carrying
known amounts offormaldehyde through the incubation
and assay procedures.
Protein Assay
The protein content of the S-15 fraction was mea-
sured by the Biuret method (24). Bovine serum albuin
was employed as the standard.
Results
The cytotoxicity of DMN in the absence of the S-15
fraction is illustrated in Table 1. The cytotoxicity
Table 1. Cytotoxicity of dimethylnitrosamine in the absence of
the S-15 fraction.
Dimethylnitrosamine, mM Cloning efficiency, %ab
0 100 ± 2.9
10 96.8 ± 6.3
50 101.4 ± 1.4
100 87.3 ± 3.1
aExpressed as a percentage of control.
bMean ± SE of 12 replicates.
produced when 100 mM DMN is titrated with various,
nontoxic (25) concentrations of S-15 protein is depicted
in Figure 1. It is apparent that the observed cytotox-
icity is biphasic in the presence of any of the five S-15
fractions.
Tb determine ifDMN-induced cytotoxicity and muta-
genicity are related, it is necessary to use a variety of
treatments such that various numbers of cells survive
each treatment and to measure the mutation frequency
of each treatment in parallel with the cytotoxicity
assessment. Toward that end, we chose to assay the
cytotoxicity and mutagenicity ofthree different concen-
trations ofDMN (10, 50 and 100 mM) in the presence of
two different concentrations ofS-15 protein (1.3 mg/mL
and 3.5 mg/mL). This protocolwas performed with S-15
fractions prepared from untreated rats as well as from
rats pretreated with four different enzyme inducers
[phenobarbitol (PB) Aroclor 1254, P-naphthoflavone
(BNF), MC]. After combining all of these data and
plotting them on one, graph (Fig. 2), it is apparent that
the log of cloning efficiency is linearly related to
mutation frequency (p < 0.01) when DMN is meta-
bolically activated by the S-15 fraction.
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FIGURE 1. Cytotoxicity of 100 mM dimethylnitrosamine in the pres-
ence ofthe S-15 fraction. S-15 fractions were derived from animals
pretreated with(o)phenobarbital, (o)Aroclor 1254, (o) ,3-naphtho-
flavone, (m)3-methylcholanthrene or (*) from animalswhich had not
beenpretreated. Cloningefficiency is expressed as a percentage of
control. Values represent the mean of three replicates.
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FIGURE 2. Relationshipbetweencytotoxicityandmutagenicitywhen
dimethylnitrosamine is incubated in the presence of the S-15
fraction (r = 0.96). Cloning efficiency is expressed as a percentage
ofcontrol. Values represent the mean ofthree replicates. Mutation
frequency was determined in the presence of 1.0 mM ouabain.
Z 5000
0
O 4000
- 3000
z
>- 2000
1-
4 1000
a
0
CZ
Ui
MUTATION FREOUENCY
0 4 8 12 16 20 34
1 1 * a a !F
I I-i
H 0 ~C]0 F
_- 0
I-
F 2 0
I-
100 50
L
10 5
S
0
j
CLONING EFFICIENCY
FIGURE 3. Relationship between ethoxyresorufin-O-deethylase
(EROD) activity in the S-15 fraction and the biological response of
V79 cells to dimethylnitrosamine: (e) Cloning efficiency expressed
as a percentage of control, values represent the mean of three
replicates; (o) mutation frequency expressed as mutants/10' viable
cells; determined in the presence of 1.0 mM ouabain. EROD
activity is expressed as pmoles resorufin/min/mg S-15 protein.
DMN is metabolically activated by an enzyme(s)
termed DMN demethylase. We wished to determine
whether DMN demethylase activity correlated with
EROD activity or with EMND activity. The experi-
mental approach for this series of experiments was
identical with that previously described for studies on
the metabolic activation of BP (25). Briefly, the experi-
ments involve modulating the enzyme pattern con-
tained in the hepatic postmitochondrial supernatant
(S-15 fraction) in two manners: (1) the hepatic enzyme
pattern is altered by pretreating experimental animals
with enzyme inducers (phenobarbital, 3-methylchol-
anthrene, 3-naphthoflavone or Aroclor 1254) and (2)
selected enzymes in the S-15 fractions prepared from
these animals are inhibited to various degrees in vitro
with metyrapone (MET) or cx-naphthoflavone (ANF).
The EMND and EROD activities in a given S-15
fraction are determined and the ability of the prepara-
tion to produce mutagenicity and/or cytotoxicity in the
presence of DMN is assessed. Correlations are made
between the EMND or EROD activity in the S-15
fraction and the biological response of V79 cells in the
presence of DMN. Since the concentration of S-15
protein in the reaction mixture markedly influences the
cytotoxicity response to DMN (Fig. 1), all samples in
this series of experiments contained equal amounts of
S-15 protein (2.4 + 0.1 mg/mL reaction mixture) while
the DMN concentration always was 100 mM.
The EROD and EMND activity in S-15 fractions
prepared from animals pretreated with selected enzyme
inducers and the influence of a-naphthoflavone and
metyrapone on these enzymes have been previously
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FIGURE 4. Relationship between ethylmorphine-N-demethvlase
(EMND) activity in the S-15 fraction and the biological response of
V79cellstodimethylnitrosamine: (e)cloningefficiency expressed as
a percentage of control; values represent the mean of three
replicates; (o) mutation frequency expressed as mutants/105 viable
cells; determined in the presence of 1.0 mM ouabain. EMND
activity is expressed as nmoles formaldehyde/min/mg S-15 protein.
reported (25). The biological responses of V79 cells to
100 mM DMN when it is metabolized by these S-15
fractions was assessed and the data were combined and
statistically analyzed as previously described (25). We
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found that DMN-induced cytotoxicity or mutagenicity
does not correlate significantly (p < 0.05) with EROD
activity (Fig. 3) or with EMND activity (Fig. 4) in the
S-15 fraction.
Discussion
The cytotoxicity curve which results when 100 mM
DMN is titrated with various amounts of S-15 protein
has a biphasic shape, regardless of whether the S-15
fraction is derived from an untreated rat or from one
which has been pretreated with MC, BNF, Aroclor 1254
or PB (Fig. 1). Maximal toxicity is seenbetween 2.1 and
3.5 mg S-15 protein/mL reaction mixture, depending on
the pretreatment used. When the concentration ofS-15
protein is 3.5 mg/mL or greater, it is apparent that an
increase in the amount of S-15 protein produces a
decrease in observed cytotoxicity. In view ofthe widely
accepted hypothesis that the metabolic activation of
DMN to a cytotoxic compound is due to a single
mixed-function oxidase catalyzed reaction, one would
anticipate that the greater the amount of mixed-
function oxidase (i.e, S-15 fraction) in the reaction
mixture, the greater the rate of DMN activation and
the greater the amount of DMN-induced cytotoxicity.
Since DMN is less cytotoxic in the presence of large
amounts ofS-15 protein when compared to intermediate
amounts, the excess protein is presumably acting as a
nucleophilic trap for the DMN metabolite(s) responsible
for cytotoxicity.
The data depicted in Figure 2 illustrate that cloning
efficiency is linearly related to mutation frequency
when DMN is metabolically activated by the S-15
fraction. This indicates either (A) the cytotoxic metabo-
lite of DMN is identical with the mutagenic metabolite
or (B) the cytotoxic and mutagenic metabolites ofDMN
are not identical, but are produced from DMN by
microsomal enzymes in a constant ratio.
The metabolic activation of DMN is catalyzed by
DMN demethylase (8). We wished to determine ifDMN
demethylase activity could be correlated with EROD
activity, a reaction catalyzed by MC-inducible mixed
function oxidases, or with EMND activity, a reaction
catalyzed by PB-inducible mixed function oxidases.
Very high concentrations of DMN (500-6700 mM)
might denature and/or cause conformational changes in
protein (26,27). However, there are numerous refer-
ences in the literature which indicate that the DMN
concentration employed in this study (s 100mM) does
not affect the activity of DMN demethylase (8,9,28).
The results ofthis study (Figs. 3 and 4) indicate thatthe
cytotoxicity and mutagenicity ofDMN neither correlate
with EROD activity nor with EMND activity. There
are several probable explanations for these results. The
mixed-function oxidases whose activities are measured
by the EROD and EMND assays are not the enzymes
which metabolically activate DMN to toxic and muta-
genic forms. Alternatively, the mixed-function oxidases
whose activities are measured by EROD and EMND
assays are responsible for the metabolic activation of
DMN, but these enzymes even when substantially
inhibited by MET or ANF, do not become rate-limiting.
Also, the metabolic activation ofDMN may be catalyzed
by any one of several mixed-function oxidases. When
one or more of these enzymes are inhibited by MET or
ANF, other forms of cytochrome P-450 are able to
compensate with little or no change in the rate ofDMN
activation.
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